DexcomDXCMEarnings & Financial Report
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
营收
$871.3M
毛利润
$546.4M
营业利润
$128.1M
净利润
$115.9M
毛利率
62.7%
营业利润率
14.7%
净利率
13.3%
同比增长
25.2%
EPS
$0.28
资金流向
Dexcom Q2 2023 Financial Summary
Dexcom reported revenue of $871.3M for Q2 2023, with a net profit of $115.9M (13.3% margin). Cost of goods sold was $324.9M, operating expenses totaled $418.3M.
Key Financial Metrics
| Total Revenue | $871.3M |
|---|---|
| Net Profit | $115.9M |
| Gross Margin | 62.7% |
| Operating Margin | 14.7% |
| Report Period | Q2 2023 |
Dexcom Annual Revenue by Year
Dexcom annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.7B).
| Year | Annual Revenue |
|---|---|
| 2025 | $4.7B |
| 2024 | $4.0B |
| 2023 | $3.6B |
| 2022 | $2.9B |
利润表
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $1.00B | $994.2M | $1.11B | $1.04B | $1.16B | $1.21B | $1.26B | $1.26B |
| 同比增长 | 15.3% | 2.0% | 7.6% | 12.5% | 15.2% | 21.6% | 13.1% | 21.6% |
资产负债表
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $6.80B | $6.35B | $6.48B | $6.75B | $7.33B | $7.50B | $6.34B | $6.34B |
| 总负债 | $4.36B | $4.37B | $4.38B | $4.49B | $4.75B | $4.77B | $3.59B | $3.59B |
| 股东权益 | $2.43B | $1.98B | $2.10B | $2.27B | $2.57B | $2.73B | $2.75B | $2.75B |
现金流量表
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| 经营性现金流 | $279.4M | $199.5M | $301.4M | $183.8M | $303.0M | $659.9M | $294.0M |
Other Health Care Companies
ABT
Abbott Laboratories
营收
$11.4B
净利润
$1.6B
BAX
Baxter International
营收
$3.0B
净利润
$-1.1B
BDX
Becton Dickinson
营收
$5.3B
净利润
$382.0M
BSX
Boston Scientific
营收
$5.3B
净利润
$670.0M
EW
Edwards Lifesciences
营收
$1.6B
净利润
$291.1M
GEHC
GE HealthCare
营收
$5.7B
净利润
$588.0M
HOLX
Hologic
营收
$1.0B
净利润
$179.1M
IDXX
Idexx Laboratories
营收
$1.1B
净利润
$274.6M
PODD
Insulet Corporation
营收
$783.7M
净利润
$101.6M
ISRG
Intuitive Surgical
营收
$2.9B
净利润
$794.8M